Back to Journals » Infection and Drug Resistance » Volume 9

A critical appraisal of once-daily topical luliconazole for the treatment of superficial fungal infections

Authors Gupta AK, Daigle D

Received 21 July 2015

Accepted for publication 13 November 2015

Published 18 January 2016 Volume 2016:9 Pages 1—6

DOI https://doi.org/10.2147/IDR.S61998

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Rekha Dhanwani

Peer reviewer comments 5

Editor who approved publication: Professor Suresh Antony

Aditya K Gupta,1,2 Deanne Daigle2

1Department of Medicine, University of Toronto School of Medicine, Toronto, 2Dermatology, Mediprobe Research Inc., London, ON, Canada

Abstract: Luliconazole is a novel imidazole derivative, which has demonstrated in vitro efficacy against dermatophytes and Candida. The results from Phase III trials show that luliconazole 1% cream applied once daily for 2 weeks successfully resolved the clinical signs and symptoms as well as eradicated the pathologic fungi, which cause tinea pedis. A 1-week treatment with luliconazole 1% cream also produced favorable clinical and mycological results in clinical trials for tinea corporis and tinea cruris. Across trials, adverse events consisted mainly of localized reactions following application. The development of a new antifungal agent is timely due to mounting resistance among existing treatments. Because luliconazole requires a short duration of treatment, it may assist in reducing disease recurrence as a result of patient nonadherence.

Keywords: antifungal, dermatophyte, athlete's foot, tinea cruris, tinea corporis, imidazole

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

Methicillin-resistant Staphylococcus aureus multiple sites surveillance: a systemic review of the literature

Chipolombwe J, Török ME, Mbelle N, Nyasulu P

Infection and Drug Resistance 2016, 9:35-42

Published Date: 12 February 2016

Monitoring cancer stem cells: insights into clinical oncology

Lin SC, Xu YC, Gan ZH, Han K, Hu HY, Yao Y, Huang MZ, Min DL

OncoTargets and Therapy 2016, 9:731-740

Published Date: 11 February 2016

Pseudomonas aeruginosa ventilator-associated pneumonia management

Ramírez-Estrada S, Borgatta B, Rello J

Infection and Drug Resistance 2016, 9:7-18

Published Date: 20 January 2016

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Cancer testis antigen and immunotherapy

Krishnadas DK, Bai F, Lucas KG

ImmunoTargets and Therapy 2013, 2:11-19

Published Date: 18 April 2013

Application of miRNA expression analysis on exfoliated colonocytes for diagnosis of colorectal cancer

Murata S, Koga Y, Moriya Y, Akasu T, Fujita S, Yamamoto S, Kakugawa Y, Ohtake Y, Saito N, Matsumura Y

Gastrointestinal Cancer: Targets and Therapy 2012, 2:11-18

Published Date: 4 May 2012